DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 165 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,244,232 | +31.8% | 97,817 | +45.9% | 0.00% | – |
Q2 2023 | $943,684 | +11.4% | 67,023 | +22.2% | 0.00% | – |
Q1 2023 | $847,479 | +82.0% | 54,853 | +93.0% | 0.00% | – |
Q4 2022 | $465,770 | -67.2% | 28,418 | -63.0% | 0.00% | -100.0% |
Q3 2022 | $1,422,000 | +400.7% | 76,863 | +256.5% | 0.00% | – |
Q2 2022 | $284,000 | -64.1% | 21,560 | -74.8% | 0.00% | – |
Q1 2022 | $792,000 | -71.5% | 85,425 | -70.0% | 0.00% | – |
Q4 2021 | $2,780,000 | +105.2% | 284,563 | +614.0% | 0.00% | – |
Q3 2021 | $1,355,000 | +232.1% | 39,853 | +337.9% | 0.00% | – |
Q1 2021 | $408,000 | -73.5% | 9,100 | -66.3% | 0.00% | -100.0% |
Q4 2020 | $1,542,000 | +94.5% | 26,999 | +74.7% | 0.00% | – |
Q3 2020 | $793,000 | -24.8% | 15,457 | -12.5% | 0.00% | – |
Q2 2020 | $1,055,000 | +13.9% | 17,671 | +18.8% | 0.00% | -100.0% |
Q4 2019 | $926,000 | +336.8% | 14,872 | +137.9% | 0.00% | – |
Q3 2019 | $212,000 | -80.9% | 6,252 | -77.9% | 0.00% | -100.0% |
Q2 2018 | $1,112,000 | – | 28,264 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
New Leaf Venture Partners, L.L.C. | 4,104,140 | $93,041,000 | 43.52% |
SV Health Investors, LLC | 1,716,303 | $38,909,000 | 20.55% |
PURA VIDA INVESTMENTS, LLC | 68,154 | $1,545,000 | 0.65% |
Redmile Group, LLC | 683,880 | $14,658,000 | 0.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 77,000 | $1,746,000 | 0.62% |
SPHERA FUNDS MANAGEMENT LTD. | 224,154 | $5,008,000 | 0.59% |
EMERALD ADVISERS, LLC | 482,626 | $10,941,000 | 0.42% |
EMERALD MUTUAL FUND ADVISERS TRUST | 416,342 | $9,438,000 | 0.38% |
Orbimed Advisors | 1,176,070 | $26,662,000 | 0.34% |
VIKING GLOBAL INVESTORS LP | 2,394,625 | $54,286,000 | 0.33% |